Literature DB >> 12717418

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells.

Terry H Landowski1, Nancy E Olashaw, Deepak Agrawal, William S Dalton.   

Abstract

The microenvironment has been shown to influence tumor cell phenotype with respect to growth, metastasis, and response to chemotherapy. We have utilized oligonucleotide microarray analysis to identify signal transduction pathways and gene products altered by the interaction of myeloma tumor cells with the extracellular matrix component fibronectin that may contribute to the antiapoptotic phenotype conferred by the microenvironment. Genes with altered expression associated with fibronectin cell adhesion, either induced or repressed, were numerically ranked by fold change. FN adhesion repressed the expression of 469 gene products, while 53 genes with known coding sequences were induced by twofold or more. Of these 53 genes with two fold, or greater increase in expression, 11 have been reported to be regulated by the nuclear factor-kappa B (NF-kappa B) family of transcription factors. EMSA analysis demonstrated NF-kappa B binding activity significantly increased in cells adhered to fibronectin compared to cells in suspension. This DNA binding activity consisted primarily of RelB-p50 heterodimers, which was distinct from the NF-kappa B activation of TNF alpha. These data demonstrate the selectivity of signal transduction from the microenvironment that may contribute to tumor cell resistance to programmed cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12717418     DOI: 10.1038/sj.onc.1206315

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  62 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 2.  Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.

Authors:  Wan Zhang; Peng Huang
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

3.  Upregulation of nuclear transporter, Kpnβ1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma.

Authors:  Song He; Xiaobing Miao; Yaxun Wu; Xinghua Zhu; Xianjing Miao; Haibing Yin; Yunhua He; Chunsun Li; Yushan Liu; Xiaoyun Lu; Yali Chen; Yuchan Wang; Xiaohong Xu
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-23       Impact factor: 4.553

Review 4.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 5.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

Review 6.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

7.  EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.

Authors:  Francesco La Rocca; Irma Airoldi; Emma Di Carlo; Pina Marotta; Geppino Falco; Vittorio Simeon; Ilaria Laurenzana; Stefania Trino; Luciana De Luca; Katia Todoerti; Oreste Villani; Martin Lackmann; Fiorella D'Auria; Francesco Frassoni; Antonino Neri; Luigi Del Vecchio; Pellegrino Musto; Daniela Cilloni; Antonella Caivano
Journal:  Cell Oncol (Dordr)       Date:  2017-07-18       Impact factor: 6.730

8.  Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Authors:  M B Meads; B Fang; L Mathews; J Gemmer; L Nong; I Rosado-Lopez; T Nguyen; J E Ring; W Matsui; A R MacLeod; J A Pachter; L A Hazlehurst; J M Koomen; K H Shain
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

9.  p52-Independent nuclear translocation of RelB promotes LPS-induced attachment.

Authors:  T Saito; C Y Sasaki; L J Rezanka; P Ghosh; D L Longo
Journal:  Biochem Biophys Res Commun       Date:  2009-11-10       Impact factor: 3.575

10.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.